SPX4,297.14+16.99 0.40%
DIA339.37+1.54 0.46%
IXIC13,128.05+80.87 0.62%

Piper Sandler Cuts Price Target For Integra Lifesciences As It Divests Wound Care Portfolio

Benzinga · 07/28/2022 05:28
  • Piper Sandler lowered the Integra Lifesciences Holdings Corp (NASDAQ:IART) to $55 from $66 and KEPT A NEUTRAL RATING on the shares.
  • Yesterday the company reported Q2 sales of $397.8 million, +4.8% on an organic basis, beating the consensus of $395.27 million and EPS of $0.82, better than the consensus of $0.80.
  • The analyst said the Q2 results "modestly" beat his top-line and bottom-line estimates on continued procedure recovery.
  • He notes that initiatives to increase efficiency and price capture are benefiting Integra despite supply chain and macro headwinds. 
  • O'Brien noted that many growth drivers are in the early stages in relatively low-growth end markets.
  • Integra agreed to divest its Traditional Wound Care Business to Gentell for $28.8 million.
  • The company tightened its organic growth expectations from 3.8% - 5.2% to 4.0% - 5.2%, reflecting the uncertainty in global markets and continuing supply constraints.
  • It forecasts FY22 revenue of $1.56 billion - $1.57 billion, down from $1.58 billion - $1.60 billion, compared to the consensus of $1.59 billion.
  • It sees FY22 EPS of $3.21 - $3.29, reflecting the planned divestiture of the wound care business.
  • For Q3, IART expects sales of $383 million - $391 million and adjusted EPS of $0.78 - $0.82, versus the consensus of $398.66 million and $0.84.
  • Price Action: IART shares closed 1.12% lower at $56.53 on Wednesday.